about
International Consensus Document (ICON): Common Variable Immunodeficiency DisordersManufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacyIntra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trialIs dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europeSelf-administered hyaluronidase-facilitated subcutaneous immunoglobulin therapy in complicated primary antibody deficiencies.Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia.Adequate patient's outcome achieved with short immunoglobulin replacement intervals in severe antibody deficiencies.Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies.On the dark side of therapies with immunoglobulin concentrates: the adverse eventsPositive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia.Lung magnetic resonance imaging with diffusion weighted imaging provides regional structural as well as functional information without radiation exposure in primary antibody deficiencies.The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacementClinical Associations of Biallelic and Monoallelic TNFRSF13B Variants in Italian Primary Antibody Deficiency Syndromes.Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies.Clinical use of polyvalent immunoglobulinsPolyvalent immunoglobulins: challenges and perspectivesEditorial: Immunoglobulin Therapy in the 21st Century - the Dark Side of the Moon.Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells.Immunoglobulin-induced hemolysis, splenomegaly and inflammation in patients with antibody deficiencies.Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group.Development and Initial Validation of a Questionnaire to Measure Health-Related Quality of Life of Adults with Common Variable Immune Deficiency: The CVID_QoL Questionnaire.Intravenous immunoglobulin replacement treatment does not alter polymorphonuclear leukocytes function and surface receptors expression in patients with common variable immunodeficiency.Otologic evaluation of patients with primary antibody deficiency.B cells from nuclear factor kB essential modulator deficient patients fail to differentiate to antibody secreting cells in response to TLR9 ligand.Intravenous immunoglobulin replacement induces an in vivo reduction of inflammatory monocytes and retains the monocyte ability to respond to bacterial stimulation in patients with common variable immunodeficiencies.A mutation in caspase-9 decreases the expression of BAFFR and ICOS in patients with immunodeficiency and lymphoproliferation.Health-Related Quality of Life and Patients' Empowerment in the Health Care of Primary Immune Deficiencies.Anti-infective prophylaxis for primary immunodeficiencies: what is done in Italian Primary Immunodeficiency Network centers (IPINet) and review of the literature.Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment.Dysregulated extracellular signal-regulated kinase signaling associated with impaired B-cell receptor endocytosis in patients with common variable immunodeficiency.ReplyHealth-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter StudyDecreased IgM, IgA, and IgG response to pneumococcal vaccine in children with transient hypogammaglobulinemia of infancyAutoimmune lymphoproliferative syndrome in pregnancy: a case of favorable mother-fetal outcome in a well-controlled diseaseIntravenous immunoglobulin replacement therapy in common variable immunodeficiency induces B cell depletion through differentiation into apoptosis-prone CD21(low) B cellsCorrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42]Hyper-IgE in the allergy clinic--when is it primary immunodeficiency?Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatmentRisk factors for Haemophilus influenzae and pneumococcal respiratory tract colonization in CVID
P50
Q26777304-1304DB44-C186-4AFD-9DE0-A47C1FF6F592Q27027732-A889C66F-BA6E-4293-A6FC-9C48E1F163C0Q27498979-CCCCBB64-7D6F-4CCE-9DF0-D76A376D6731Q33419638-67ECD980-48A6-4B05-B629-B7A3DC8E490FQ33434307-1C551E5F-C5F3-4AFA-AFEA-42442869F560Q33438302-1E735455-F7F0-44FF-9AFE-01555CED6A6CQ34196132-261F05F0-B857-4F92-9792-47D3D7FF7E02Q34574119-FCA35560-A088-40E4-AA41-27AE62F83B60Q35053458-2D52793E-70EB-4064-A6A6-C6DDC9321E7AQ35409531-B06B7039-E0AD-4911-A697-0E5ACFA1F481Q35851600-3CB1AB3D-4DBA-44CC-95CB-C6EC328FC53FQ36350848-839B62D8-7B05-4DA9-9F46-0A3558F4306BQ36792808-415A0266-5AE6-4992-B1C0-4EABC04CE42EQ37706062-D4C820A9-380B-468F-820B-6C09F337183CQ38170872-52DCED36-8540-4D15-8E76-8DBA81255171Q38170873-2D85D585-55AE-47BB-9FA8-7133AE0DDAE7Q38422333-FDA729A3-1F14-45AD-A804-1D3BC08DD045Q38697505-17B2EA9D-4A3C-4AD6-B9FB-6E8056DF19BDQ38725835-5EE9DF65-994B-4ED7-8099-B2FBB9DEA8F6Q40134778-8555F16E-EF52-41D9-93D9-722EC3C5C951Q40528457-B101EDF2-21B7-4C4B-8344-09E59BD364FBQ40644703-3991213B-350F-4D36-8129-280A6B7A350CQ40770347-83100D8E-7D24-4171-B4C0-16F493218CFEQ41033426-568BFFFE-6C07-449A-BE52-B683415F24A7Q41077885-103088C5-6B29-4712-92A8-3F3C1840D636Q41609169-2BE037C8-0BCA-49BD-A77F-2B903E6B3867Q42358569-1052728C-A951-4A85-A9D3-9C93DDCD87A4Q43825070-830B3FEA-BD56-4910-9D49-1B8DCDE09AABQ50454680-C6CBF7BD-B3F2-455E-BA76-19C37BC7C9E3Q50850510-674EC695-A181-4C83-9433-8EAAA9802426Q62658753-7EF981C0-3851-4892-AA97-30B81152940EQ64292734-1052DB4C-E260-4609-9848-BC733042A37BQ85696794-630B6116-5E51-4A02-AA61-CB2A8886481BQ85741434-6D4101C7-3437-47E2-8DB7-4163ACBA3FFBQ86017374-6FCDDB3E-A6B3-47B1-BB01-AFB525EDA6F3Q89783592-3DADB9A8-C8F1-4C60-BCE1-BE906025F0D5Q90462395-63A38775-DFB4-40D1-B3A5-6B0ADDD7755AQ90875249-E17521A0-D778-4649-9A91-133DDC49BED5Q91251056-94473F42-0A80-4A22-8BFE-3A1CF7CBC03A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Isabella Quinti
@ast
Isabella Quinti
@en
Isabella Quinti
@es
Isabella Quinti
@nl
type
label
Isabella Quinti
@ast
Isabella Quinti
@en
Isabella Quinti
@es
Isabella Quinti
@nl
prefLabel
Isabella Quinti
@ast
Isabella Quinti
@en
Isabella Quinti
@es
Isabella Quinti
@nl
P106
P1153
7006456490
P21
P31
P496
0000-0002-3328-7584